• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Aromatase inhibitors superior to tamoxifen in reducing ER positive breast cancer recurrence

byXiaozhou Liu
July 29, 2015
in Chronic Disease, Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this meta-analysis of randomized controlled trials, estrogen receptor (ER) positive breast cancer recurrence rate was lower with an aromatase inhibitor over tamoxifen during years 0-1 and 2-4, but not thereafter.

2. Overall 10-year breast cancer mortality favored aromatase inhibitors. The incidence of endometrial cancer was also reduced with aromatase inhibitors compared to tamoxifen.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Breast cancer is a leading cause of cancer deaths for women in developed countries. It is further classified into subtypes based on hormonal receptor positivity for treatment and prognostic purposes. In this meta-analysis of randomized controlled trials, the investigators compared aromatase inhibitors to tamoxifen in preventing recurrence and death for patients with ER positive breast cancer. Results showed that aromatase inhibitors were superior to tamoxifen during the earlier years (0-1 and 2-4) of follow-up in reducing recurrence (rate ratio = 0.85), but not thereafter. The 10-year overall mortality was found to be lower with aromatase inhibitors than with tamoxifen. The incidence of endometrial cancer was also lower with aromatase inhibitors compared to tamoxifen. The study was strengthened by the large number of patients (31 920) included in the final analyses. A potential weakness is that the study did not factor into compliance.

The study was funded by Cancer Research UK, Medical Research Council.

Click to read the study in The Lancet

RELATED REPORTS

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts

Relevant Reading: Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

In-Depth [meta-analysis]: This meta-analysis included data from 31920 women in 9 trials. Eligible trials began in 2005 and randomized post-menopausal women to receive either an aromatase inhibitor or tamoxifen during various time frames in treatment. The primary outcomes were any recurrence of breast cancer, breast cancer mortality, and all-cause mortality.

In comparing 5 years of aromatase inhibitor versus 5 years of tamoxifen (comparison A, 2 trials, n = 9885), there were fewer recurrences with aromatase inhibitors (p<0.00001), with significant reductions during years 0-1 post-op (rate-ratio, RR, 0.64, 95% CI 0.52-0.78), and during years 2-4 (RR 0.80, 95% CI 0.68 – 0.93). There was no significant effect after the scheduled treatment period. The 10-year recurrence risk was lower with aromatase inhibitors (difference 3.6%, 95% CI, 1.7 – 5.4). 10-year breast cancer mortality was lower with aromatase inhibitors (RR 0.85, 95% CI 0.75 – 0.96, 2p=0.009).

In comparing 5 years of aromatase inhibitors versus 2-3 years of tamoxifen then an aromatase inhibitor to year 5 (comparison B, 3 trials, n = 12779), there was a smaller but statistically significant reduction in total recurrence with aromatase inhibitors compared to tamoxifen-aromatase inhibitors (2p = 0.045). There was no significant reductions in breast cancer mortality (2p = 0.11) or all-cause mortality.

In comparing 2-3 years of tamoxifen then an aromatase inhibitor to year 5 versus 5 years of tamoxifen (comparison C, 6 trials, n = 11798), allocation to an aromatase inhibitor reduced the recurrence rate during years 2-4 (RR 0.56, 95% CI 0.46 – 0.67, p<0.0001). Breast cancer mortality was reduced (RR 0.84, 95% CI 0.77 – 0.97, 2p=0.015), as was all-cause mortality (2p=0.0002).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancer
Previous Post

Lung cancer screening may lower motivation for smoking cessation

Next Post

Improved self reported coverage and access following ACA open enrollment

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Chronic Disease

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

July 2, 2025
3D mammography (tomosynthesis) enhances accuracy of breast cancer screening
Chronic Disease

Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts

June 25, 2025
#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
StudyGraphics

#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

June 17, 2025
Next Post
Adjuvant breast cancer treatment associated with additional cancer risk

Improved self reported coverage and access following ACA open enrollment

Designer molecule targets key protein in tenosynovial giant-cell tumor

Designer molecule targets key protein in tenosynovial giant-cell tumor

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact

Mild hypothermia for deceased organ donors reduces the rate of delayed graft function in renal transplants

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.